Ideaya Biosciences is trading at $35.87, down -4.24%, as broad risk-off trading and weaker biotechnology sentiment weigh on shares.
- Nasdaq is down 0.87%, while XBI is down 2.04%, supporting a macro- and sector-led explanation; elevated Treasury yields and inflation concerns are among the cited pressures.
- No new company-specific announcement was identified on September 24, 2026; the latest official release concerned the OptimUM-11 Phase 3 trial.